Skin Cancer/Melanoma
Chronic Immune-Related Adverse Events Are Common in Certain Melanoma Subgroups
April 17, 2021
Article
Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
April 12, 2021
Article
Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.
FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma
February 09, 2021
Article
The FDA approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.
FDA Grants Toripalimab Fast Track Status for Mucosal Melanoma
January 26, 2021
Article
The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma, according to an announcement from Junshi Biosciences, the drug developer.
Precision Medicine Highlights the Importance of Biomarkers in Melanoma
December 04, 2020
Article
With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.
Tebentafusp Boosts Survival in Metastatic Uveal Melanoma
November 25, 2020
Article
Tebentafusp (IMCgp100) showed superiority in overall survival (OS) compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma, according to results of a preplanned interim analysis of the phase 3 IMCgp100-202 trial (NCT03070392).
Cemiplimab Is Promising for Metastatic Basal Cell Carcinoma Treatment
November 18, 2020
Article
Cemiplimab (Libtayo) demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma (mBCC) after progression on or intolerance to hedgehog inhibitors.
Cabozantinib Plus Pembrolizumab May Improve Melanoma Outcomes
November 13, 2020
Article
In an effort to further improve outcomes without sacrificing tolerability, the combination of cabozantinib (Cabometyx) with pembrolizumab (Keytruda) is being evaluated in patients with advanced melanoma in a phase 1b/2 study (NCT03957551), according to a virtual presentation during the 2020 SITC Annual Meeting.
Predicting Immunotherapy Response in Melanoma
November 11, 2020
Article
Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1 Now, investigators are working to answer more questions about this group of patients.
How To Choose Immunotherapy or BRAF-Targeted Treatment for Adjuvant Melanoma
November 08, 2020
Article
There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.